LIDOCAINE
Benign Renal Neoplasm
Hans BahlmannSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Benign Renal Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Hans Bahlmann | Phase 3 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Hans Bahlmann | Phase 3 | B |
Pyruvate Zhen Wang, MD | Phase 2 | CCC |
Urea Zhen Wang, MD | Phase 2 | CCC |
Same molecule, other indications
LIDOCAINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →